Why the study?
Does statin treatment reduce the progression of rheumatic mitral stenosis in asymptomatic patients?
Does statin treatment reduce the progression of rheumatic mitral stenosis in asymptomatic patients?
Statin therapy is associated with significantly slower echocardiographic progression of rheumatic mitral stenosis over long-term follow-up.
Answers are grounded in this paper and cite their sources.
Statin use was associated with slower rheumatic mitral stenosis progression; leaves open randomized confirmation before practice change.
BACKGROUND: At present, no medical therapy is known to affect the progression of rheumatic mitral stenosis (MS). We sought to assess the effect of statin treatment on long-term progression of MS in a large population. METHODS AND RESULTS: From our 20-year database, we identified all patients with rheumatic MS with > or =2 echocardiographies > or =1 year apart. Exclusion criteria were previous intervention on the mitral valve, more than moderate aortic regurgitation, or symptoms at first examination. The study sample included 315 patients (mean age, 61+/-12 years; 224 women); 35 patients (11.1%) were treated with statins, and 280 (88.9%) were not. Mean follow-up period was 6.1+/-4.0 years (range, 1 to 20). The rate of decrease in mitral valve area was significantly lower in the statin group compared with the untreated group (0.027+/-0.056 versus 0.067+/-0.082 cm(2)/y; P=0.005). The annualized change in mean transmitral gradient was lower in statin-treated patients (0.20+/-0.59 versus 0.58+/-0.96 mm Hg/y; P=0.023). The prevalence of fast MS progression (annual change in mitral valve area >0.08 cm(2)) was significantly lower in the statin group (P=0.008). An increase in systolic pulmonary artery pressure of >10 mm Hg was found in 17% of patients in the statin group versus 40% of untreated patients (P=0.045). CONCLUSIONS: Our study shows a significantly slower progression of rheumatic MS in patients treated with statins. These findings could have an important impact in the early medical therapy of patients with rheumatic heart disease.
No takes yet. Share an insight, caveat, or question.
Antonini‐Canterin et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: